The pharmaceutical pricing landscape has taken another curious turn. Canadians are now accessing cheaper generic versions of the blockbuster diabetes drug Ozempic, while American patients continue to pay a significant premium. The divergence highlights a growing chasm in drug pricing that the market appears unable to resolve without government intervention.
For years, the City has watched the Ozempic saga with a mixture of fascination and frustration. The drug, a GLP-1 receptor agonist developed by Novo Nordisk, has become a cash cow for the Danish company. But its pricing structure is a classic example of market inefficiency: the same molecule costs vastly different amounts depending on which side of the Atlantic you happen to be standing.
Canadians, through their national healthcare system, have negotiated a price for the generic version that is roughly 80% lower than the U.S. list price. The UK, with its National Institute for Health and Care Excellence (NICE) and the Pharmaceutical Price Regulation Scheme (PPRS), has similarly managed to keep prices in check. The result is a pricing model that the financial press has been forced to applaud, even if it makes the free-marketeers wince.
Let's be clear: this is not about charity. It is about negotiating power. The UK and Canada have monopsony buyers who can walk away from the table. The U.S. has a fragmented system where insurers and pharmacy benefit managers (PBMs) engage in a complex dance of rebates and discounts that often obscures the true cost. The bottom line? The U.S. pays more, and the shareholders of Novo Nordisk smile all the way to the bank.
The praise for the UK pricing model is particularly telling. The PPRS, a voluntary agreement between the government and the pharmaceutical industry, caps spending on branded medicines. Companies can set their launch prices freely, but if overall sales exceed the cap, they must repay the excess. It is a clever mechanism that aligns the interests of the taxpayer and the innovator. The result is that the UK gets Ozempic at a price that is roughly a third of the U.S. list price.
But do not expect a free lunch. The UK's approach is not without its critics. Some argue that the PPRS stifles innovation by limiting returns on investment. Yet the data suggests otherwise. The UK remains a top destination for clinical trials and new drug launches. The model has been praised by the World Health Organisation and is being studied by countries from Japan to Brazil.
The Canadian situation is slightly different. The generic Ozempic, produced by a Canadian manufacturer under licence, is available for about $300 a month compared to over $1,000 in the U.S. The Canadian government, through the Patented Medicine Prices Review Board (PMPRB), has been aggressive in capping prices. The result is a market that is both cheaper and more stable, but one that raises questions about long-term supply and investment.
For the American patient, the situation is a bitter pill. The Inflation Reduction Act, passed in 2022, includes provisions for Medicare to negotiate prices on a handful of drugs, but Ozempic is not among them yet. The U.S. remains the land of the free and the home of the brave, but also of the high drug price. The market is clearing at a price that many cannot afford.
What does this mean for investors? The differential pricing is a double-edged sword. On one hand, it allows companies like Novo Nordisk to maximize profits by charging high prices in the U.S. while still making sales in lower-price markets. On the other hand, it creates political risk. The U.S. Congress is increasingly looking at drug pricing reforms, and the generics floodgate is opening.
The UK model, despite its bureaucratic label, is more efficient than critics admit. It uses a combination of health technology assessment and price controls to achieve a balance. It is not perfect. There have been shortages and delays. But for a country with a fixed budget for healthcare, it is a model that keeps the fiscal wolves at bay.
For now, the Canadian and UK patients get their medicine at a price that does not break the bank. The American patient, meanwhile, is left with a choice: pay up or find a loophole. The market is speaking, and the message is clear: government intervention can work, even if it makes the true believers in free markets uncomfortable.
